Autoantibodies: Opportunities for Early Cancer Detection
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening
The National Lung Screening Trial Research Team (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102873 · Cited by 11,064
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447 · cited 1×
“However, recent studies suggest that this ability to predict the efficacy of combination therapies may be limited [108,109].”
BackgroundCancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474 · cited 1×
“It is now generally accepted that the immune system recognizes these cell abnormalities early in their development and initiates a response [133,134] that has three phases.”
BackgroundCancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
Delves, P. J., & Roitt, I. M. (2000) · New England Journal of Medicine · doi:10.1056/nejm200007063430107 · Cited by 1,666
CD20+ B Cells: The Other Tumor-Infiltrating Lymphocytes
Nelson, B. H. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1001323 · Cited by 416
PD-1 is a novel regulator of human B-cell activation
Thibult, M.-L., Mamessier, E., Gertner-Dardenne, J., Pastor, S., Just-Landi, S., Xerri, L., Chetaille, B., & Olive, D. (2013) · International Immunology · doi:10.1093/intimm/dxs098 · Cited by 365 · cited 1×
“It is also well documented that PD1 is strongly involved in the regulation of B cells [110,111].”
BackgroundHow antibodies to a ubiquitous cytoplasmic enzyme may provoke joint-specific autoimmune disease
Matsumoto, I., Maccioni, M., Lee, D. M., Maurice, M., Simmons, B., Brenner, M., Mathis, D., & Benoist, C. (2002) · Nature Immunology · doi:10.1038/ni772 · Cited by 329
Cited by
Crosby, D., Bhatia, S., Brindle, K. M., Coussens, L. M., Dive, C., Emberton, M., Esener, S., Fitzgerald, R. C., Gambhir, S. S., Kuhn, P., et al. (2022) · Science · doi:10.1126/science.aay9040 · Cited by 1,379
B cells, plasma cells and antibody repertoires in the tumour microenvironment
Sharonov, G. V., Serebrovskaya, E. O., Yuzhakova, D. V., Britanova, O. V., & Chudakov, D. M. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0257-x · Cited by 627
Tumour-infiltrating B cells: immunological mechanisms, clinical impact and therapeutic opportunities
Laumont, C. M., Banville, A. C., Gilardi, M., Hollern, D. P., & Nelson, B. H. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00466-1 · Cited by 524
Peña-Romero, A. C., & Orenes-Piñero, E. (2022) · Cancers · doi:10.3390/cancers14071681 · Cited by 257
Universal cancer screening: revolutionary, rational, and realizable
Ahlquist, D. A. (2018) · npj Precision Oncology · doi:10.1038/s41698-018-0066-x · Cited by 135
Qiu, C., Wang, X., Batson, S. A., Wang, B., Casiano, C. A., Francia, G., & Zhang, J.-Y. (2023) · Cancers · doi:10.3390/cancers15164064 · Cited by 9
Metadata
- Authors
- Macdonald, I. K., Parsy-Kowalska, C. B., & Chapman, C. J.
- Venue
- Trends in Cancer
- Publisher
- Elsevier BV
- Published
- 2017-03
- Volume
- 3
- Issue
- 3
- Pages
- 198-213
- ISSN
- 2405-8025 (ISSN-L)
- 2405-8033
- OpenAlex
- W2594170573
- Cited by
- 162
- References
- 8
- FWCI
- 1.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.